Sacituzumab Tirumotecan
Trials 93 · started per year
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT07702305 | Jun 2026 → Dec 2027 expected | neoplastic meningitis | Henan Cancer Hospital | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06049212 | Oct 2023 → Jun 2026 overdue | non-small cell lung carcinoma | Merck Sharp & Dohme LLC | Active not recruiting | No outcome recorded |
| Phase 1/210 trials | ||||||
| Phase 1/2 | NCT07286149 | Apr 2026 → Aug 2031 expected | lung cancer | Merck Sharp & Dohme LLC | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07139470 | Aug 2025 → Apr 2027 expected | triple-negative breast carcinoma | Tianjin Medical University Cancer Institute and Hospital | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT06780111 | Jul 2025 → Jan 2032 expected | esophageal squamous cell carcinoma | Merck Sharp & Dohme LLC | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06637423 | Dec 2024 → Mar 2029 expected | non-invasive bladder urothelial carcinoma | Merck Sharp & Dohme LLC | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06469944 | Sep 2024 → Sep 2029 expected | esophageal cancer, gastroesophageal adenocarcinoma, gastroesophageal junction adenocarcinoma | Merck Sharp & Dohme LLC | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06445972 | Aug 2024 → May 2028 expected | esophageal cancer, gastroesophageal adenocarcinoma, gastroesophageal junction adenocarcinoma | Merck Sharp & Dohme LLC | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06483334 | Jul 2024 → Mar 2028 expected | urothelial carcinoma | Merck Sharp & Dohme LLC | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT06428409 | Jun 2024 → Oct 2029 expected | biliary tract cancer, colorectal cancer, pancreatic ductal adenocarcinoma | Merck Sharp & Dohme LLC | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05319730 | May 2023 → Jun 2027 expected | esophageal squamous cell carcinoma | Merck Sharp & Dohme LLC | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04152499 | Feb 2020 → Dec 2026 expected | breast cancer, cervical cancer, endometrial carcinoma, gastric adenocarcinoma +6 | Klus Pharma Inc. | Active not recruiting | No outcome recorded |
| Phase 255 trials | ||||||
| Phase 2 | NCT07521670 | Nov 2026 → Oct 2028 expected | salivary gland adenoid cystic carcinoma, thyroid gland papillary carcinoma | National Cancer Centre, Singapore | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07511023 | Sep 2026 → Mar 2031 expected | squamous cell carcinoma | M.D. Anderson Cancer Center | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07701681 | Aug 2026 → Sep 2028 expected | esophageal squamous cell carcinoma, gastric adenocarcinoma, gastroesophageal junction adenocarcinoma | Sun Yat-sen University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07639086 | Aug 2026 → Mar 2030 expected | prostate cancer, prostate neuroendocrine neoplasm | Virginia Commonwealth University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07697586 | Aug 2026 → Aug 2028 expected | non-small cell lung carcinoma | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07689292 | Jul 2026 → Aug 2027 expected | gastric adenocarcinoma, gastroesophageal junction adenocarcinoma | Tianjin Medical University Cancer Institute and Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07662863 | Jul 2026 → Dec 2028 expected | peripheral neuropathy, urinary bladder cancer, urothelial carcinoma | Fudan University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07701122 | Jul 2026 → Jul 2027 expected | biliary tract cancer | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07686588 | Jul 2026 → Dec 2027 expected | head and neck carcinoma | Biying Chen | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07438626 | Jun 2026 → Jun 2028 expected | SMARCB1-deficient kidney medullary carcinoma | M.D. Anderson Cancer Center | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07324629 | Jun 2026 → Apr 2028 expected | thymic carcinoma | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06706219 | May 2026 → Nov 2028 expected | non-small cell lung carcinoma | Hunan Province Tumor Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07343479 | May 2026 → Jun 2027 expected | metastatic malignant neoplasm in the brain, non-small cell lung carcinoma | Zhejiang Cancer Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07579598 | May → Dec 2026 expected | salivary gland adenoid cystic carcinoma | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07458113 | May 2026 → May 2028 expected | triple-negative breast carcinoma | Yale University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07545213 | Apr 2026 → Feb 2028 expected | non-small cell lung carcinoma | The Fourth Affiliated Hospital of Zhejiang University School of Medicine | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07670013 | Apr 2026 → Jan 2028 expected | non-small cell lung carcinoma | Second Affiliated Hospital, School of Medicine, Zhejiang University | Recruiting | No outcome recorded |
| Phase 2 | NCT07561463 | Apr 2026 → Jan 2027 expected | pancreatic ductal adenocarcinoma | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07501169 | Apr 2026 → Aug 2027 expected | small cell lung carcinoma | Sichuan University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07329322 | Mar 2026 → Aug 2027 expected | non-small cell lung carcinoma | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT07466927 | Mar 2026 → Jan 2028 expected | Her2-receptor negative breast cancer | Fudan University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07471776 | Mar 2026 → Mar 2028 expected | Her2-receptor negative breast cancer | Fudan University | Recruiting | No outcome recorded |
| Phase 2 | NCT07388875 | Feb 2026 → Feb 2027 expected | small cell lung carcinoma | China Medical University, China | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07348861 | Feb 2026 → Jan 2028 expected | cervical cancer | Zheng Min | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07548060 | Feb 2026 → Jan 2028 expected | non-small cell lung carcinoma | Tianjin Medical University Cancer Institute and Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT07256236 | Jan 2026 → Jun 2028 expected | cervical cancer | Fujian Cancer Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT07341100 | Jan 2026 → Jan 2028 expected | malignant epithelial tumor of ovary | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 2 | NCT07323056 | Jan → Jun 2026 overdue | non-small cell lung carcinoma | Shanghai Pulmonary Hospital, Shanghai, China | Recruiting | No outcome recorded |
| Phase 2 | NCT07623577 | Jan 2026 → Jan 2027 expected | metastatic malignant neoplasm in the brain, triple-negative breast carcinoma | Fudan University | Recruiting | No outcome recorded |
| Phase 2 | NCT07314619 | Dec 2025 → Dec 2027 expected | — | The First Affiliated Hospital of Zhengzhou University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07371208 | Dec 2025 → Aug 2028 expected | breast cancer | Shanghai Jiao Tong University School of Medicine | Recruiting | No outcome recorded |
| Phase 2 | NCT07343453 | Dec 2025 → Dec 2027 expected | thymic epithelial neoplasm | Sun Yat-sen University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07375316 | Dec 2025 → Jun 2028 expected | non-small cell lung carcinoma | Guangdong Association of Clinical Trials | Recruiting | No outcome recorded |
| Phase 2 | NCT07244874 | Dec 2025 → Jan 2028 expected | triple-negative breast carcinoma | Tianjin Medical University Cancer Institute and Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07244926 | Dec 2025 → Jun 2027 expected | lung cancer | Tianjin Medical University Cancer Institute and Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07193160 | Nov 2025 → Jul 2026 overdue | non-small cell lung carcinoma | Fudan University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07054242 | Oct 2025 → Oct 2026 expected | female breast carcinoma | Yantai Yuhuangding Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07197008 | Oct 2025 → Dec 2027 expected | lung cancer | Li-kun Chen | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07182721 | Sep 2025 → Sep 2028 expected | HER2 positive breast carcinoma | Fudan University | Recruiting | No outcome recorded |
| Phase 2 | NCT07179783 | Sep 2025 → Jun 2027 expected | castration-resistant prostate carcinoma, prostate adenocarcinoma, prostate neuroendocrine neoplasm | Tianjin Medical University Second Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT07153965 | Sep 2025 → Sep 2026 expected | triple-negative breast carcinoma | Tianjin Medical University Cancer Institute and Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07109284 | Sep 2025 → Jan 2028 expected | estrogen-receptor positive breast cancer | West China Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07128693 | Sep 2025 → Dec 2028 expected | esophageal squamous cell carcinoma | The First Affiliated Hospital of Zhengzhou University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07007780 | Aug 2025 → Aug 2026 overdue | triple-negative breast carcinoma | Xijing Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07108816 | Aug 2025 → Dec 2026 expected | — | Henan Cancer Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07703228 | Aug 2025 → Sep 2027 expected | metastatic neoplasm, non-small cell lung carcinoma | Nanfang Hospital, Southern Medical University | Active not recruiting | No outcome recorded |
| Phase 2 | NCT07088211 | Jul 2025 → Aug 2027 expected | head and neck squamous cell carcinoma | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | Recruiting | No outcome recorded |
| Phase 2 | NCT07105852 | Jul 2025 → Jul 2027 expected | cholangiocarcinoma | Sir Run Run Shaw Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT06849492 | Apr 2025 → Dec 2027 expected | triple-negative breast carcinoma | Fudan University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06145308 | Aug 2023 → Jul 2028 expected | salivary gland carcinoma | Peking Union Medical College | Recruiting | No outcome recorded |
| Phase 2 | NCT05816252 | Apr 2023 → Jun 2026 overdue | non-small cell lung carcinoma | Klus Pharma Inc. | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05642780 | Jan 2023 → Nov 2027 expected | cancer | Klus Pharma Inc. | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05631262 | Nov 2022 → Dec 2026 expected | — | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05445908 | Aug 2022 → Sep 2027 expected | breast carcinoma | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05351788 | May 2022 → Aug 2026 overdue | non-small cell lung carcinoma | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 325 trials | ||||||
| Phase 3 | NCT07628504 | May 2026 → Mar 2030 expected | — | Fudan University | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07419295 | Apr 2026 → Jul 2029 expected | urinary bladder cancer | Merck Sharp & Dohme LLC | Recruiting | No outcome recorded |
| Phase 3 | NCT07318558 | Feb 2026 → Feb 2033 expected | ovarian cancer | Merck Sharp & Dohme LLC | Recruiting | No outcome recorded |
| Phase 3 | NCT07216703 | Jan 2026 → Oct 2031 expected | cervical cancer | Merck Sharp & Dohme LLC | Recruiting | No outcome recorded |
| Phase 3 | NCT07071337 | Jul 2025 → Jul 2027 expected | Her2-receptor negative breast cancer | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT06966700 | Jun 2025 → Mar 2033 expected | triple-negative breast carcinoma | Merck Sharp & Dohme LLC | Recruiting | No outcome recorded |
| Phase 3 | NCT06952504 | May 2025 → May 2032 expected | endometrial cancer | Merck Sharp & Dohme LLC | Recruiting | No outcome recorded |
| Phase 3 | NCT06824467 | Apr 2025 → Apr 2029 expected | fallopian tube cancer, ovarian cancer, primary peritoneal carcinoma | Merck Sharp & Dohme LLC | Recruiting | No outcome recorded |
| Phase 3 | NCT06841354 | Mar 2025 → May 2030 expected | triple-negative breast carcinoma | Merck Sharp & Dohme LLC | Recruiting | No outcome recorded |
| Phase 3 | NCT06670196 | Nov 2024 → May 2027 expected | non-small cell lung carcinoma | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06711900 | Oct 2024 → Dec 2026 expected | non-small cell lung carcinoma | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06459180 | Jul 2024 → Jun 2028 expected | cervical cancer | Merck Sharp & Dohme LLC | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06393374 | Jun 2024 → Dec 2030 expected | triple-negative breast carcinoma | Merck Sharp & Dohme LLC | Recruiting | No outcome recorded |
| Phase 3 | NCT06305754 | Jun 2024 → Aug 2028 expected | non-small cell lung carcinoma | Merck Sharp & Dohme LLC | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06422143 | Jun 2024 → Jan 2029 expected | non-small cell lung carcinoma | Merck Sharp & Dohme LLC | Recruiting | No outcome recorded |
| Phase 3 | NCT06448312 | Jun 2024 → Nov 2026 expected | non-small cell lung carcinoma | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06356311 | May 2024 → Jan 2027 expected | gastroesophageal cancer | Merck Sharp & Dohme LLC | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06312176 | Apr 2024 → Jul 2027 expected | breast neoplasm | Merck Sharp & Dohme LLC | Recruiting | No outcome recorded |
| Phase 3 | NCT06312137 | Apr 2024 → Feb 2034 expected | non-small cell lung carcinoma | Merck Sharp & Dohme LLC | Recruiting | No outcome recorded |
| Phase 3 | NCT06279364 | Feb 2024 → Jul 2026 overdue | triple-negative breast carcinoma | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT06170788 | Dec 2023 → Jan 2028 expected | non-small cell lung carcinoma | Merck Sharp & Dohme LLC | Recruiting | No outcome recorded |
| Phase 3 | NCT06132958 | Dec 2023 → Jan 2028 expected | endometrial cancer | Merck Sharp & Dohme LLC | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06074588 | Nov 2023 → May 2027 expected | non-small cell lung carcinoma | Merck Sharp & Dohme LLC | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06081959 | Oct 2023 → Dec 2026 expected | breast cancer | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT05870319 | Jun 2023 → Jul 2024 overdue | non-small cell lung carcinoma | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT07068542 | Jul 2025 → Dec 2027 expected | differentiated thyroid carcinoma, poorly differentiated thyroid gland carcinoma | Zhejiang Provincial People's Hospital | Recruiting | No outcome recorded |
Also used as a comparator or background therapy in 5 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07157956 Background | Sep 2025 → Aug 2028 expected | neoplasm | Convalife (Shanghai) Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT06992739 Background | Dec 2025 → Mar 2027 expected | bone marrow failure syndrome, non-small cell lung carcinoma | The First Affiliated Hospital of Xiamen University | Recruiting | No outcome recorded |
| Phase 2 | NCT06851299 Comparator | Mar 2025 → Apr 2027 expected | triple-negative breast carcinoma | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT05347134 Comparator | Jun 2022 → Nov 2023 overdue | triple-negative breast carcinoma | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT06230055 Background | Jan 2024 → Jan 2026 overdue | Her2-receptor negative breast cancer, malignant leptomeningeal tumor | Fudan University | Recruiting | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 99 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Sacituzumab tirumotecan | “The OptiTROP-Breast01 phase 3 trial assessed sacituzumab tirumotecan (sac-TMT) versus chemotherapy in patients with locally recurrent or metastatic TNBC who had received two or...” PMID 40217078 ↗ Apr 202578“A Phase II Clinical Study to Evaluate Sacituzumab Tirumotecan (SKB264) in Combination With SKB118 for the Treatment of Participants With Locally Advanced or Metastatic...” NCT07697586 ↗ “Sacituzumab tirumotecan (sac-TMT, also known as MK-2870 or SKB264) is an antibody-drug conjugate targeting trophoblast cell surface antigen 2.” PMID 40830660 ↗ Aug 2025 “Sacituzumab tirumotecan combined with third-generation EGFR-TKI with or without intracranial radiotherapy” NCT07343479 ↗ “Sacituzumab tirumotecan (sac-TMT), a trophoblast cell-surface antigen 2-targeting antibody-drug conjugate” PMID 42214392 ↗ May 2026 “Sacituzumab Tirumotecan (SKB264) Plus Glecirasib (KRAS G12C Inhibitor)” NCT07670013 ↗ “CVL006（B006 Injection）、SKB264（Sacituzumab tirumotecan）” NCT07157956 ↗ “sacituzumab tirumotecan 5 mg/kg IV q2w” NCT06145308 ↗ “Sacituzumab Tirumotecan (Sac-TMT)” NCT07371208 ↗ |
| Known as | Lukang-sacituzumab | “This study investigates the synergistic efficacy and safety of combining Lukang-sacituzumab (SKB264/MK-2870), a third-generation TROP2-directed antibody-drug conjugate (ADC),...” NCT07703228 ↗ |
| Known as | MK-2870 | “This study investigates the synergistic efficacy and safety of combining Lukang-sacituzumab (SKB264/MK-2870), a third-generation TROP2-directed antibody-drug conjugate (ADC),...” NCT07703228 ↗2“Sacituzumab tirumotecan (sac-TMT, also known as MK-2870 or SKB264) is an antibody-drug conjugate targeting trophoblast cell surface antigen 2.” PMID 40830660 ↗ Aug 2025 “sacituzumab tirumotecan (MK-2870)” NCT07511023 ↗ |
| Known as | Sac-TMT | “This study is a Phase I, single-arm, single-center, dose-escalation clinical trial designed to investigate the safety and efficacy of intrathecal injection of sacituzumab...” NCT07702305 ↗18“This is an open-label, investigator-initiated phase II clinical trial designed to evaluate the efficacy and safety of Sacituzumab Tirumotecan (sac-TMT) monotherapy in patients...” NCT07521670 ↗ “The OptiTROP-Breast01 phase 3 trial assessed sacituzumab tirumotecan (sac-TMT) versus chemotherapy in patients with locally recurrent or metastatic TNBC who had received two or...” PMID 40217078 ↗ Apr 2025 “A Single Arm, Phase II Study of Sacituzumab Tirumotecan（Sac-TMT） Combined With Toripalimab for First-line Treatment of PD-L1 Positive Unresectable Locally Advanced/Metastatic...” NCT07244874 ↗ “This is an single-arm, multicenter phase II study to evaluate the safety and efficacy of Sacituzumab Tirumotecan (sac-TMT) plus anlotinib in previously treated extensive-stage...” NCT07501169 ↗ “Multicenter, Phase II Clinical Study of Sacituzumab Tirumotecan (Sac-TMT) in Combination With Fruquintinib as Second-Line Therapy for Advanced Gastric/Gastroesophageal Junction...” NCT07689292 ↗ “An Open-label, Single-arm, Multicenter Phase I/II Study of Sacituzumab Tirumotecan (Sac-TMT) Plus Anlotinib in Previously Treated Metastatic Triple Negative Breast Cancer (mTNBC).” NCT07139470 ↗ “Sacituzumab tirumotecan (sac-TMT, also known as MK-2870 or SKB264) is an antibody-drug conjugate targeting trophoblast cell surface antigen 2.” PMID 40830660 ↗ Aug 2025 “Sacituzumab Tirumotecan (sac-TMT) is administered intravenously at a dose of 4 mg/kg on Day 1 of each 3-week cycle for a total of 8 cycles.” NCT07628504 ↗ “Sacituzumab tirumotecan (sac-TMT), a trophoblast cell-surface antigen 2-targeting antibody-drug conjugate” PMID 42214392 ↗ May 2026 “Sacituzumab tirumotecan (sac-TMT) is an antibody-drug conjugate (ADC) directed against TROP2.” NCT07639086 ↗ “Sacituzumab tirumotecan (Sac-TMT; also known as SKB264) for injection.” NCT07324629 ↗ “Sacituzumab Tirumotecan (Sac-TMT/SKB264) Plus Tagitanlimab (KL-A167)” NCT07701681 ↗ “Sacituzumab Tirumotecan (Sac-TMT) plus Tagitanlimab” NCT07153965 ↗ “Sacituzumab tirumotecan (Sac-TMT) plus bevacizumab” NCT07197008 ↗ “Biological: Sacituzumab Tirumotecan (sac-TMT)” NCT06469944 ↗ “Sacituzumab Tirumotecan (Sac-TMT)” NCT07623577 ↗ “Sacituzumab Tirumotecan (Sac-TMT)” NCT07371208 ↗ |
| Known as | SKB264 | “This study investigates the synergistic efficacy and safety of combining Lukang-sacituzumab (SKB264/MK-2870), a third-generation TROP2-directed antibody-drug conjugate (ADC),...” NCT07703228 ↗29“Study Title: Safety and Efficacy of Intrathecal Injection of Sacituzumab Tirumotecan (SKB264) in the Treatment of Leptomeningeal Metastasis from EGFR-TKI-Resistant Non-Small...” NCT07702305 ↗ “A Phase II Clinical Study to Evaluate Sacituzumab Tirumotecan (SKB264) in Combination With SKB118 for the Treatment of Participants With Locally Advanced or Metastatic...” NCT07697586 ↗ “Participants will receive treatment with a Trop-2-targeting ADC drug containing a TOP1 inhibitor (such as Gosituzumab or SKB264), in accordance with the defined protocol.” NCT06851299 ↗ “Sacituzumab Tirumotecan (SKB264) is a humanized antibody-drug conjugate (ADC) targeting TROP2, which is often overexpressed in SCLC.” NCT07388875 ↗ “Sacituzumab Tirumotecan (SKB264): The initial dosage is 5 mg/kg, administered intravenously every two weeks.” NCT07579598 ↗ “Sacituzumab tirumotecan (Sac-TMT; also known as SKB264) for injection.” NCT07324629 ↗ “Sacituzumab Tirumotecan (Sac-TMT/SKB264) Plus Tagitanlimab (KL-A167)” NCT07701681 ↗ “Drug: Sacituzumab Tirumotecan (SKB264)” NCT07701122 ↗ “Sacituzumab Tirumotecan (SKB264)” NCT07068542 ↗ “SKB264(5mg/kg, d1, q2w, ivgtt)” NCT06230055 ↗ |
| Action | Deplete | “attaches to specific targets on cancer cells and delivers treatment to destroy those cells” NCT07216703 ↗ |
| Modality | Other / unclassified | “Sacituzumab tirumotecan (sac-TMT, also known as MK-2870 or SKB264) is an antibody-drug conjugate targeting trophoblast cell surface antigen 2.” PMID 40830660 ↗ Aug 2025 |
| Route | Intravenous | “Patients will receive study drug as a single IV infusion at the prescribed dose level at each administration.” NCT04152499 ↗ |